245 related articles for article (PubMed ID: 36814687)
1. Phytochemical Comparison of Medicinal Cannabis Extracts and Study of Their CYP-Mediated Interactions with Coumarinic Oral Anticoagulants.
Treyer A; Reinhardt JK; Eigenmann DE; Oufir M; Hamburger M
Med Cannabis Cannabinoids; 2023; 6(1):21-31. PubMed ID: 36814687
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants.
Bansal S; Zamarripa CA; Spindle TR; Weerts EM; Thummel KE; Vandrey R; Paine MF; Unadkat JD
Clin Pharmacol Ther; 2023 Sep; 114(3):693-703. PubMed ID: 37313955
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.
Zamarripa CA; Spindle TR; Surujunarain R; Weerts EM; Bansal S; Unadkat JD; Paine MF; Vandrey R
JAMA Netw Open; 2023 Feb; 6(2):e2254752. PubMed ID: 36780161
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions.
Nasrin S; Watson CJW; Perez-Paramo YX; Lazarus P
Drug Metab Dispos; 2021 Dec; 49(12):1070-1080. PubMed ID: 34493602
[TBL] [Abstract][Full Text] [Related]
5. ¹H NMR and HPLC/DAD for Cannabis sativa L. chemotype distinction, extract profiling and specification.
Peschel W; Politi M
Talanta; 2015 Aug; 140():150-165. PubMed ID: 26048837
[TBL] [Abstract][Full Text] [Related]
6. The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications.
Qian Y; Gurley BJ; Markowitz JS
J Clin Psychopharmacol; 2019; 39(5):462-471. PubMed ID: 31433338
[TBL] [Abstract][Full Text] [Related]
7. Absorbance-Transmittance Excitation Emission Matrix Method for Quantification of Major Cannabinoids and Corresponding Acids: A Rapid Alternative to Chromatography for Rapid Chemotype Discrimination of
Gilmore AM; Elhendawy MA; Radwan MM; Kidder LH; Wanas AS; Godfrey M; Hildreth JB; Robinson AE; ElSohly MA
Cannabis Cannabinoid Res; 2023 Oct; 8(5):911-922. PubMed ID: 35486823
[No Abstract] [Full Text] [Related]
8. Assessing the bioactivity of cannabis extracts in larval zebrafish.
Nixon J; Abramovici H; Cabecinha A; Martinez-Farina C; Hui J; Ellis L
J Cannabis Res; 2021 Oct; 3(1):44. PubMed ID: 34598738
[TBL] [Abstract][Full Text] [Related]
9. The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination.
Robaina Cabrera CL; Keir-Rudman S; Horniman N; Clarkson N; Page C
Pulm Pharmacol Ther; 2021 Aug; 69():102047. PubMed ID: 34082108
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: a Full-Spectrum Characterization.
Doohan PT; Oldfield LD; Arnold JC; Anderson LL
AAPS J; 2021 Jun; 23(4):91. PubMed ID: 34181150
[TBL] [Abstract][Full Text] [Related]
11. Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity.
Yamaori S; Koeda K; Kushihara M; Hada Y; Yamamoto I; Watanabe K
Drug Metab Pharmacokinet; 2012; 27(3):294-300. PubMed ID: 22166891
[TBL] [Abstract][Full Text] [Related]
12. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review.
Stout SM; Cimino NM
Drug Metab Rev; 2014 Feb; 46(1):86-95. PubMed ID: 24160757
[TBL] [Abstract][Full Text] [Related]
13. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
De Petrocellis L; Ligresti A; Moriello AS; Allarà M; Bisogno T; Petrosino S; Stott CG; Di Marzo V
Br J Pharmacol; 2011 Aug; 163(7):1479-94. PubMed ID: 21175579
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of cannabis extracts and pure plant cannabinoids on hippocampal neurones and glia.
Ryan D; Drysdale AJ; Pertwee RG; Platt B
Neurosci Lett; 2006 Nov; 408(3):236-41. PubMed ID: 16997463
[TBL] [Abstract][Full Text] [Related]
15. Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile.
Swift W; Wong A; Li KM; Arnold JC; McGregor IS
PLoS One; 2013; 8(7):e70052. PubMed ID: 23894589
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid-Induced Inhibition of Morphine Glucuronidation and the Potential for In Vivo Drug-Drug Interactions.
Coates S; Bardhi K; Lazarus P
Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543313
[TBL] [Abstract][Full Text] [Related]
17. Prediction of Carboxylesterase 1-mediated In Vivo Drug Interaction between Methylphenidate and Cannabinoids using Static and Physiologically Based Pharmacokinetic Models.
Qian Y; Markowitz JS
Drug Metab Dispos; 2022 Jul; 50(7):968-979. PubMed ID: 35512806
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoids in clinical practice.
Williamson EM; Evans FJ
Drugs; 2000 Dec; 60(6):1303-14. PubMed ID: 11152013
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid receptor 1 binding activity and quantitative analysis of Cannabis sativa L. smoke and vapor.
Fischedick J; Van Der Kooy F; Verpoorte R
Chem Pharm Bull (Tokyo); 2010 Feb; 58(2):201-7. PubMed ID: 20118579
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Inhibition of Carboxylesterase 1 by Major Cannabinoids and Selected Metabolites.
Qian Y; Wang X; Markowitz JS
Drug Metab Dispos; 2019 May; 47(5):465-472. PubMed ID: 30833288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
